TREM-1 作为一个与透明细胞肾细胞癌免疫浸润相关的潜在预后生物标志物。
TREM-1 as a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma.
机构信息
Taizhou Hospital of Zhejiang Province, Shao Xing University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
Department of Radiation Oncology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, No. 150 Ximen Street, TaizhouZhejiang, 317000, Linhai, China.
出版信息
World J Surg Oncol. 2023 May 23;21(1):156. doi: 10.1186/s12957-023-03013-w.
BACKGROUND
The tumor immune microenvironment plays a crucial role in the efficacy of various therapeutics. However, their correlation is not yet completely understood in Clear cell renal cell carcinoma (ccRCC). This study aimed to investigate the potential of TREM-1 as a potential novel biomarker for ccRCC.
METHODS
We constructed a ccRCC immune prognostic signature. The clinical characteristics, the status of the tumor microenvironment, and immune infiltration were analyzed through the ESTIMATE and CIBERSORT algorithms for the hub gene, while the Gene Set Enrichment Analysis and PPI analysis were performed to predict the function of the hub gene. Immunohistochemical staining was used to detect the expression of TREM-1 in renal clear cell carcinoma tissues.
RESULTS
The CIBERSORT and ESTIMATE algorithms revealed that TREM-1 was correlated with the infiltration of 12 types of immune cells. Therefore, it was determined that TREM-1 was involved in numerous classical pathways in the immune response via GSEA analysis. In Immunohistochemical staining, we found that the expression of TREM-1 was significantly upregulated with increasing tumor grade in renal clear cell carcinoma, and elevated TREM-1 expression was associated with poor prognosis.
CONCLUSIONS
The results suggest that TREM-1 may act as an implicit novel prognostic biomarker in ccRCC that could be utilized to facilitate immunotherapeutic strategy.
背景
肿瘤免疫微环境在各种治疗方法的疗效中起着至关重要的作用。然而，在透明细胞肾细胞癌（ccRCC）中，它们之间的相关性尚不完全清楚。本研究旨在探讨 TREM-1 作为 ccRCC 潜在新型生物标志物的潜力。
方法
我们构建了 ccRCC 免疫预后特征。通过 ESTIMATE 和 CIBERSORT 算法分析了该基因的临床特征、肿瘤微环境状态和免疫浸润情况，而通过基因集富集分析（GSEA）和 PPI 分析预测了该基因的功能。采用免疫组织化学染色法检测 TREM-1 在肾透明细胞癌组织中的表达。
结果
CIBERSORT 和 ESTIMATE 算法表明，TREM-1 与 12 种免疫细胞的浸润有关。因此，通过 GSEA 分析确定 TREM-1 参与了免疫反应中的许多经典途径。免疫组织化学染色结果显示，在肾透明细胞癌中，TREM-1 的表达随着肿瘤分级的增加而显著上调，且高表达 TREM-1 与预后不良相关。
结论
这些结果表明，TREM-1 可能作为 ccRCC 中隐含的新型预后生物标志物，可用于辅助免疫治疗策略。
Zotero 插件